| Cat. No. |
Product Name |
CAS No. |
Information |
| PC-62804 |
SEMBL
|
1443448-82-5 |
SEMBL is a potent NF-κB inhibitor that inhibits DNA binding of NF-κB component p65. |
| PC-60551 |
NDMC101
|
1308631-40-4 |
NDMC101 is a small molecule that inhibits NFATc1 and NF-κB activity, inhibits RANKL-induced osteoclastogenesis in vivo. |
| PC-60550 |
ABD328
|
1055896-19-9 |
ABD328 (ABD-328) is an orally active, small molecule inhibitor of RANKL and TNF signalling that inhibits inflammation in vivo. |
| PC-49360 |
IT848
|
2102435-79-8 |
IT848 (IT-848) is a potent and specific small molecule NF-κB inhibitor, decreases the affinity of NF-κB all five subunits (Rel A, Rel B, c-Rel, p50 and p52) to their DNA binding sites and disrupts downstream biological events. |
| PC-49334 |
sRANKL inhibitor S3-15
|
2412947-15-8 |
sRANKL inhibitor S3-15 is a highly potent, orally active inhibitor of soluble RANKL, selectively interrupt soluble RANKL-RANK interaction and without interfering with the membrane RANKL-RANK interaction, shows potent osteoclast inhibition effect with IC50 of 0.19 uM in vitro. |
| PC-49234 |
Y1693
|
|
Y1693 is a potent, orally active small-molecule RANKL inhibitor, effectively prevents RANKL-induced osteoclastogenesis (89% inhibition at 1 uM) and bone resorption. |
| PC-47045 |
CRL1101
|
328010-30-6 |
CRL1101 is a small-molecule inhibitor of RelA, binds specifically to RelA (KD=2.3 uM, MST assays) and blockes RelA nuclear translocation in breast cancer cells. |
